Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Ocugen, Inc.

NASDAQ: OCGN · Life Sciences · 10 alerts · CIK 1372299

Ocugen, Inc. stories on ALFA USA NewsRead the news →
Share price
$0.7730Close, Nov 16
Market cap
$262M
Shares outstanding
339.31MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Ocugen, Inc. filings on SEC EDGAR ↗

8:31 AM ET 8-K
Licensing Deal

Ocugen Licensing Deal with Celairis Therapeutics Holdings Pty Ltd Worth $7.1M

Ocugen granted Celairis Therapeutics an exclusive license to commercialize its OCU400 gene therapy for retinitis pigmentosa in Australia, New Zealand, and ASEAN markets. Ocugen will receive up to $7.1 million in upfront and milestone payments, plus high single-digit royalties and 50% of gross profits from net sales. Ocugen retains sole manufacturing rights and expects to enter a formal supply agreement within 90 days.

Value
$7.1M
Counterparty
Celairis Therapeutics Holdings Pty Ltd
Term
20 years
6:07 AM ET 8-K
Licensing Deal

Ocugen Licensing Deal with Roots Pharmaceutical Company WLL Worth $259M

Ocugen granted Roots Pharmaceutical an exclusive license to commercialize OCU400, a modifier gene therapy for retinitis pigmentosa, in the Middle East and North Africa. Ocugen will receive up to $4 million in upfront and development milestones, up to $255 million in sales milestones, and a 22% royalty on net sales. Ocugen also entered into a commercial supply agreement to manufacture the product for Roots.

Value
$259M
Counterparty
Roots Pharmaceutical Company WLL
Term
20 years from first commercial sale

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.